Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 2-8 moderate to severe migraines/month within the last 3 months~* Migraine attacks present for more than 1 year with age of onset of migraines prior to 50 years of age~* Migraine attacks, on average, lasting about 4-72 hours if untreated~* Less than 15 days with headaches (migraine or non-migraine) per month in each of the 3 months prior to the screening visit~* Ability to distinguish migraine attacks from tension/cluster headaches~* Participants with contraindications for use of triptans may be included provided they meet all other study entry criteria~Exclusion Criteria:~* History of human immunodeficiency virus disease~* History of basilar or hemiplegic migraine~* Current diagnosis of major depressive disorder requiring treatment with atypical antipsychotics, schizophrenia, bipolar disorder, or borderline personality disorder~* History of nasal surgery in the 6 months preceding the screening visit~* History of gallstones or cholecystectomy~* History of gastric, or small intestinal surgery (including gastric bypass, gastric banding, gastric sleeve, gastric balloon, etcetera), or other disease or condition (for example, chronic pancreatitis, ulcerative colitis, etcetera) that causes malabsorption.~* Body mass index ≥ 33~* Hemoglobin A1c ≥6.5%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zavegepant (BHV-3500) (Type: EXPERIMENTAL): 10 mg intranasal (IN) up to 8 times per month, up to 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).